Author

Elena Jachetti

Fondazione IRCCS Istituto Nazionale dei TumoriORCID 0000-0001-6483-7350Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Francesco CreaiD· 2 shared Irene FischettiiD· 2 shared Mario Paolo ColomboiD· 2 shared Mark EcclestoniD· 2 shared Maryam LataraniiD· 2 shared Yuzhuo Z. WangiD· 2 shared Adam R. BrentnalliD· 1 shared Antonino BelfioreiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Francesco CreaORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 1, 2026

ENPP3 expressed by HER2-positive breast cancer cells is associated with good prognosis by restraining epithelial-to-mesenchymal phenotype

Roberta Bongiorno, Maria Teresa Majorini, Valeria Figa'…·Daniele Lecis

This study shows that ENPP3 expression in HER2-positive breast cancer cells is linked to better prognosis by inhibiting epithelial-to-mesenchymal transition.

DOI 10.64898/2026.08.31.747828

mousehuman

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 25, 2026

Pharmacological targeting of EED is an effective therapeutic strategy in cellular models of incurable neuroendocrine prostate cancer

Kayleigh J. A. Orchard, George Bryant, Maryam Latarani…·Francesco Crea

This study compares tazemetostat and ORIC-944 in NEPC and PRAD cells, finding ORIC-944 more effective in inducing apoptosis and growth inhibition.

DOI 10.64898/2026.02.24.707688

humanbulk RNA-seq

𝕏 PostBluesky

Pharmacology & ToxicologyEpigenomicsPeer-reviewedJan 29, 2025

EZH2 inhibition enhances the activity of platinum chemotherapy in aggressive variant prostate cancer

Maryam Latarani, Perla Pucci, Mark Eccleston…·Francesco Crea

This study shows that EZH2 inhibition enhances platinum chemotherapy effectiveness in aggressive variant prostate cancer by reducing H3K27me3 and modulating DNA repair and apoptosis pathways.

6 citations

humanbulk RNA-seq

𝕏 PostBluesky